| 4 FORM 1—ANTI-VIRAL DRU | GS | ID Number | Visit No. | | PATE | |
|---|-----------|--|--------------|-------------------------------------|---------|---------|
| | | | | ○ Jan | DAY | YEA |
| COMPLETE THE FOLLOWING FOR EACH DRUG LISTE | DIN | 0000 | 00 | Feb | | \perp |
| QUESTION 18.A(2). | | 00000 | 00 | O Mar | 00 | |
| 2 TO (Fairly Laminudina) Delavirdina (De | | 22222 | 22 | O Apr | 10 (1) | |
| ∃-TC (Epivir, Lamivudine) Abacavir (Ziagen) Delavirdine (Re Efavirenz (Sust | | 3 3 3 3 3 3 4 4 4 4 | 3 3 3 | May | 20 2 | 100 |
| Adefovir (Preveon) Indinavir (Crixiv | | 5 5 5 5 | 5 5 | JuneJuly | 30 3 | |
| Amprenavir (Agenerase) Nelfinavir (Vira | | 6666 | 6 6 | O Aug | (5) | 10. |
| AZT (Retrovir, Zidovudine) Nevirapine (Vir | | 7777 | 77 | Sept | 6 | |
| Combivir (AZT & 3-TC) Ritonavir (Norv | | 8888 | 8 8 | Oct | 7 | |
| Od4T (Zerit, Stavudine) Saquinavir (Inv | | | 9 9 | O Nov | (8) | |
| ○ ddC (dideoxycytidine, HIVID, Zalcitabine) ○ Other — | | | | ODec | 9 | |
| ○ ddI (dideoxyinosine, Didanosine, Videx) | | | | | | |
| Name | of Drug: | | Drug Cod | | | |
| and the second experience are an experience | | - | | 00 000 400 500 | | - |
| You said you were taking (DRUG) since your last visit: | | | | 0 30 40 50 | | |
| 1.A. Did you take this drug as part of a research study? | I | | 0 1 | 2 3 4 5 | (6) (7) | (8) |
| NO (GO TO Q2) YES | 2 Are voi | currently taking | this drug l | not as na | rt of a | |
| 0 NO (GO 10 GZ) 0 TES | | h study]? | , tillo alag | not do pu | it oi u | |
| B. Was this study one in which you may have taken a | ONO | | YES (GC | TO (04) | | |
| placebo (not the actual drug) or in which you were | | | | | | |
| blinded to the treatment? | | S, BUT DRUG WA | | | | |
| ○ NO ○ YES | PART | OF A TRIAL, RE | DRUG FOR | | ETEA | • |
| | | 100000000000000000000000000000000000000 | 1 0 1 | | 1 | |
| C. Was this part of the AIDS Clinical Trial Group (ACTG)? | | your last visit] In | | h and yea | r did y | you |
| ONO (GO TO F) ODON'T KNOW (GO TO F) | | ecently take this | drug? | | | |
| ○ YES | ○ Jan | YEAR | | | | |
| D. If YES, do you know the ACTG number? | ○ Feb | | | | | |
| NO (GO TO F) YES | Mar | 92 | | | | |
| ONO (GOTOF) OTES | O Apr | | | | | |
| E. What is the number of that study? | June | | | | | |
| 0 100 200 300 400 500 600 700 600 900 | O July | | | | | |
| 0 10 20 30 40 50 60 70 80 90 | O Aug | The state of the s | | | | |
| 0 1 2 3 4 5 6 7 8 9 | O Sept | | | | | |
| | Oct | 99 | | | | |
| F. Are you currently taking this drug as part of the | O Nov | 00 | | | | |
| research study? | O Dec | 01) | | | | |
| ○ NO YES | | | | | | |
| IF YES: STOP IF PARTICIPANT WAS BLINDED TO | | start taking this | _ | your last | visit | ? |
| THE TREATMENT; IF UNBLINDED, SKIP TO Q4. | ONO | (GO TO Q6) | YES | | | |
| G. [Since your last visit] In what month and year | E (Cines) | your last visit] In | what mont | h and was | r did . | |
| did you most recently take this drug as part of | | king this drug? | what mont | n and yea | r did y | you |
| Jan YEAR the research study? | Jan | YEAR | | | | |
| Feb T | Feb | TEAN | | | | |
| Mar 92 | O Mar | 92) | | | | |
| O Apr 93 | ○ Apr | 93) | | | | |
| ○ May 94 | ○ May | | | | | |
| June 95 | June | | | | | |
| July 96 | O July | | | | | |
| O Aug 97 | O Aug | | | | | |
| ◯ Sept 98 | ○ Sept | | | | | |
| Oct 99 | Oct | 99 | | | | |
| ○ Nov ⑩ | O Nov | 00 | | | | |
| O Dec 01 | | | | | | |

STOP IF PARTICIPANT WAS BLINDED TO THE TREATMENT AND GO TO NEXT DRUG.

Mark Reflex® by NCS EM-203768-10:654321 Printed in U.S.A.

Please continue on the other side.

| Since your last visit in (MONTH), how long have you sed this (DRUG)? | 8. Did you stop taking this drug at any time since your last visit? [DOES NOT INCLUDE ALTERNATING |
|--|---|
| One week or less | DRUG USE] |
| ○ More than 1 week but less than 1 month ○ 1–2 months | ○ NO (GO TO Q10) ○ YES |
| 3–4 months | |
| 5-6 months | |
| More than 6 months | |
| | |
| 7. Have you experienced any of the following side eff | |
| from this drug? | 9. Why did you stop taking this drug? |
| (MARK ALL THAT APPLY) | (MARK ALL THAT APPLY) |
| Low white blood cells (low neutrophils) | Low white blood cells (low neutrophils) |
| Anemia (low red blood cells/low hemoglobin) | Anemia (low red blood cells/low hemoglobin) |
| Bleeding | Bleeding |
| Dizziness/Headaches | O Dizziness/Headaches |
| ○ Nausea/Vomiting | O Nausea/Vomiting |
| Abdominal pain (pancreatitis/abdominal bloating/cr | amps) Abdominal pain (pancreatitis/abdominal bloating/cramps) |
| Muscle pain or weakness (myopathy/myositis/muscle) | cle Muscle pain or weakness (myopathy/myositis/muscle |
| cramps/spasms) | cramps/spasms) |
| Burning/tingling in extremities | Burning/tingling in extremities |
| (neuropathy/neuritis/numbness) | (neuropathy/neuritis/numbness) |
| O Diarrhea | O Diarrhea |
| ○ Kidney stones | ○ Kidney stones |
| Rash | Rash |
| ○ High blood sugar/Diabetes | High blood sugar/Diabetes |
| High cholesterol/High triglycerides | High cholesterol/High triglycerides |
| O Painful urination | O Painful urination |
| ○ High blood pressure | ○ High blood pressure |
| Fat maldistribution | O Fat maldistribution |
| Nightmares/Vivid dreams | Nightmares/Vivid dreams |
| Liver toxicity (abnormal liver function test) | Liver toxicity (abnormal liver function test) |
| Other, specify: | ○ Increased viral load |
| | O Decreased viral load |
| 1) | Hospitalized |
| 2) | O Personal decision |
| | Prescription changes by physician |
| 3) | Too expensive |
| 4/4 | Too much bother, inconvenient (ran out/vacation/unable |
| None of the above | to fill prescription) |
| | Changed to another drug in order to decrease the |
| | number of pills or dosing frequency |
| | Other, specify: |
| | |
| | 1) |
| | 2) |
| | |
| | 3) |
| | |
| | |
| | 10. On average, how often did you take your medication |
| | as prescribed? |
| | • |
| | 100% of the time |
| | 95–99% of the time |
| | 75–94% of the time |

<75% of the time